secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2026-05-28T21:09:53+00:00
Accession:  0001104659-26-067614
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics raises ~$5M in registered direct offering at $0.5855/share; warrants repriced
--------------------------------------------------------------------------------

- Gross proceeds of ~$5.0M from sale of 8,539,709 shares at $0.5855 per share.
- Warrant amendment reduces exercise price of 15,488,570 warrants from $1.78 to $0.5855.
- Offering expected to close May 29, 2026; net proceeds for working capital and general corporate purposes.
- Purchaser GMS Ventures is affiliated with directors Yezan Haddadin and Faisal G. Sukhtian.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926067614/0001104659-26-067614-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926067614/tm2615925d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-067614

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer